358 related articles for article (PubMed ID: 28120446)
1. Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β
Yamaguchi O; Ikeda Y; Ohkawa S
Low Urin Tract Symptoms; 2017 Jan; 9(1):38-45. PubMed ID: 28120446
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of the Selective β3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study.
Yamaguchi O; Marui E; Igawa Y; Takeda M; Nishizawa O; Ikeda Y; Ohkawa S
Low Urin Tract Symptoms; 2015 May; 7(2):84-92. PubMed ID: 26663687
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
[TBL] [Abstract][Full Text] [Related]
5. Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.
Chapple CR; Kaplan SA; Mitcheson D; Blauwet MB; Huang M; Siddiqui E; Khullar V
Int J Urol; 2014 Oct; 21(10):960-7. PubMed ID: 25092441
[TBL] [Abstract][Full Text] [Related]
6. Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.
Yamaguchi O; Marui E; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Ikeda Y; Ohkawa S
BJU Int; 2014 Jun; 113(6):951-60. PubMed ID: 24471907
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
[TBL] [Abstract][Full Text] [Related]
8. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
[TBL] [Abstract][Full Text] [Related]
9. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
11. Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet.
Herschorn S; Staskin D; Schermer CR; Kristy RM; Wagg A
Drugs Aging; 2020 Sep; 37(9):665-676. PubMed ID: 32725584
[TBL] [Abstract][Full Text] [Related]
12. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
Herschorn S; Barkin J; Castro-Diaz D; Frankel JM; Espuna-Pons M; Gousse AE; Stölzel M; Martin N; Gunther A; Van Kerrebroeck P
Urology; 2013 Aug; 82(2):313-20. PubMed ID: 23769122
[TBL] [Abstract][Full Text] [Related]
13. Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study.
Kato D; Tabuchi H; Uno S
Low Urin Tract Symptoms; 2019 Jan; 11(1):14-23. PubMed ID: 28762672
[TBL] [Abstract][Full Text] [Related]
14. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.
Nozawa Y; Kato D; Tabuchi H; Kuroishi K
Low Urin Tract Symptoms; 2018 May; 10(2):122-130. PubMed ID: 27860325
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study.
Yoshida M; Nozawa Y; Kato D; Tabuchi H; Kuroishi K
Low Urin Tract Symptoms; 2019 Jan; 11(1):30-38. PubMed ID: 28901041
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
Khullar V; Amarenco G; Angulo JC; Cambronero J; Høye K; Milsom I; Radziszewski P; Rechberger T; Boerrigter P; Drogendijk T; Wooning M; Chapple C
Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126
[TBL] [Abstract][Full Text] [Related]
17. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
Kakizaki H; Lee KS; Yamamoto O; Jong JJ; Katou D; Sumarsono B; Uno S; Yamaguchi O
Eur Urol Focus; 2020 Jul; 6(4):729-737. PubMed ID: 31718957
[TBL] [Abstract][Full Text] [Related]
18. A phase II dose-ranging study of mirabegron in patients with overactive bladder.
Chapple CR; Dvorak V; Radziszewski P; Van Kerrebroeck P; Wyndaele JJ; Bosman B; Boerrigter P; Drogendijk T; Ridder A; Van Der Putten-Slob I; Yamaguchi O;
Int Urogynecol J; 2013 Sep; 24(9):1447-58. PubMed ID: 23471546
[TBL] [Abstract][Full Text] [Related]
19. Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy.
Shin JH; Kim A; Choo MS
Investig Clin Urol; 2017 Jul; 58(4):261-266. PubMed ID: 28681036
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]